The comparison between retatrutide and tirzepatide is the most relevant one in the GLP-1 drug class right now, because both drugs share the GIP and GLP-1 receptor mechanisms. The difference — retatrutide’s additional glucagon receptor activation — is what determines whether the extra efficacy justifies the extra regulatory risk. Tirzepatide is FDA approved under the brand name Zepbound for weight loss and Mounjaro for type 2 diabetes. Retatrutide is not approved anywhere. This comparison looks at the data on both sides.
Mechanism: Dual vs Triple Agonist
Tirzepatide is a dual GIP/GLP-1 receptor agonist. Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist. The single additional receptor — glucagon — is what accounts for most of the difference in efficacy. Professor Richard DiMarchi of Indiana University, who helped pioneer multi-receptor peptide design, describes the difference as dual agonist being a good drug and triple agonist being a fundamentally different approach. The glucagon component increases energy expenditure in ways that GIP and GLP-1 cannot replicate.
Weight Loss: TRIUMPH vs SURMOUNT
The weight loss comparison is straightforward. Tirzepatide’s SURMOUNT-1 trial showed 18-20% average weight loss at 72 weeks. Retatrutide’s TRIUMPH-4 trial showed 28.7% at 68 weeks. TRIUMPH-1 showed 28.3% at 80 weeks and 30.3% at 104 weeks in the high-BMI subgroup. The 8-10 percentage point gap is consistent across all completed trials. In practical terms, a person weighing 250 pounds would lose roughly 45-50 pounds on tirzepatide and roughly 65-70 pounds on retatrutide, based on the trial averages.
Side Effects Profile Compared
Both drugs share the same class of gastrointestinal side effects. Nausea rates are 30-40% for tirzepatide and 30-40% for retatrutide in their respective Phase 3 trials. The heart rate increase of 2-5 bpm is specific to retatrutide and related to the glucagon receptor activation. Tirzepatide does not cause a measurable heart rate increase. This is a trade-off: higher weight loss comes with a cardiovascular signal that needs longer-term data to assess.
Leave a Reply